Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: Renal and hormonal effects

References

• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Enalapril Survival Study. N Engl J Med 1987; 316: 1429–35
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
   PubMed Web of Science ®Google Scholar
• Cohn J N., Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dini-trate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10
   PubMed Web of Science ®Google Scholar
• Kleber F X., Niemöller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J 1992; 67: 289–96
   PubMedGoogle Scholar
• Pfeffer J M., Pfeffer M A., Braunwald E. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation 1987; 75(suppl I)I-149–I-155
   Google Scholar
• Goetz K L. Physiology and pathophysiology of atrial peptides. Am J Physiol 1988; 254: E1–E15
   PubMed Web of Science ®Google Scholar
• Goy M F. cGMP: the wayward child of the cyclic nucleotide family. Trends Neurosci 1991; 14: 293–9
   PubMedGoogle Scholar
• Margulies K B., Heublein D M., Perrella M A., Burnett J C. ANF-mediated renal cGMP production in congestive heart failure. Am J Physiol 1991; 260: F562–8
   Google Scholar
• Weil J, Lang R E., Suttmann H, Rampff U, Bidling-maier F, Gerzer R. Concomitant increase in plasma atrial natriuretic peptide and cyclic GMP during volume loading. Klin Wochenschr 1985; 63: 1265–8
   PubMedGoogle Scholar
• Cody R J., Atlas S A., Kubo S H., et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest 1986; 78: 1362–74
   PubMed Web of Science ®Google Scholar
• Riegger G AJ, Kromer E P., Kochsiek K. Human atrial natriuretic peptide: plasma levels, hemodynamic, hormonal and renal effects in patients with severe congestive heart failure. J Car-diovasc Pharmacol 1986; 8: 1107–12
   PubMedGoogle Scholar
• Kohzugi M. Hodsman GP, Harrison RW, Johnston CI. Attenuated renal response to atrial natriuretic peptide infusion in rats with heart failure. Clin Exp Pharmacol Physiol 1988; 15: 323–6
   PubMedGoogle Scholar
• Tikkanen T, Tikkanen I, Sariola H, Svartsröm-Fraser M, Fyhrquist F. Attenuated diuretic and natriuretic effects of atrial natriuretic peptide in rats with heart failure. Horm Metabol Res 1989; 21: 185–8
   PubMedGoogle Scholar
• Drexler H, Hanze J, Finckh M, Lu W, Just H, Lang R E. Atrial natriuretic peptide in a rat model of cardiac failure. Circulation 1989; 79: 620–33
   PubMed Web of Science ®Google Scholar
• Moe G W., Angus C, Howard R J., De Bold A J., Armstrong P W. Pathophysiological role of changing atrial size and pressure in modulation of atrial natriuretic factor during evolving experimental heart failure. Cardiovasc Res 1990; 24: 570–7
   PubMedGoogle Scholar
• Kenny A J., Bowes M A., Gee N S., Matsas R. Endo-peptidase-24.11: a cell surface enzyme for metabolizing regulatory peptides. Biochem Soc Trans 1985; 13: 293–5
   PubMedGoogle Scholar
• Gros C, Souque A, Schwartz J-C. Inactivation of atrial natriuretic factor in mice in vivo: crucial role of enkephalinase (EC 3.4.24.11). Eur J Pharmacol 1990; 179: 45–56
   PubMedGoogle Scholar
• Sonnenberg J L., Sakane Y, Jeng A Y., et al. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 1988; 9: 173–80
   PubMed Web of Science ®Google Scholar
• Lefrançois P, Clerc G, Duchier J, et al. Antihypertensive activity of sinorphan. Lancet 1990; 336: 307–8
   PubMed Web of Science ®Google Scholar
• Sybertz E J., Chiu P J., Vemulapalli S, et al. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in des-oxycorticoserone acetate-sodium hypertensive rats. J Pharmacol Exp Ther 1989; 250: 624–31
   PubMed Web of Science ®Google Scholar
• Sybertz E J., Chiu P JS, Vemulapalli S, Watkins R, Haslanger M F. Atrial natriuretic factor-potentiat-ing and antihypertensive activity of SCH 34826, an orally active neutral metalloendopeptidase inhibitor. Hypertension 1990; 15: 152–61
   PubMedGoogle Scholar
• Gros C, Souque A, Schwartz J-C, et al. Protection of atrial natriuretic factor against degradation: Diuretic and natriuretic responses after in vivo inhibition of enkephalinase (E.C. 3.4.24.11) by acetor-phan. Proc Natl Acad Sci 1989; 86: 5780–4
   Google Scholar
• Northridge D B., Jardine A G., Alabaster C T., et al. Effects of UK 69578: a novel atriopeptidase inhibitor. Lancet 1989; ii: 591–3
   Google Scholar
• Bralet J, Mossiat C, Lecomte J-M, Charpentier S, Gros C, Schwartz J-C. Diuretic and natriuretic responses in rats treated with enkephalinase inhibitors. Eur J Pharmacol 1990; 179: 57–64
   PubMedGoogle Scholar
• O'Connell J E., Jardine A G., Davidson G, Connell J MC. Candoxatril, an orally active neutral enso-peptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992; 10: 271–7
   PubMed Web of Science ®Google Scholar
• Kahn J C., Patey M, Dubois-Rande J L., et al. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990; 335: 118–9
   PubMed Web of Science ®Google Scholar
• Helin K, Tikkanen I, Tikkanen T, et al. Prolonged neutral endopeptidase inhibition in heart failure. Eur J Pharmacol 1991; 198: 23–30
   PubMed Web of Science ®Google Scholar
• Pfeffer M A., Pfeffer J M., Fishbein M C., et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979; 44: 503–12
   PubMed Web of Science ®Google Scholar
• Tsunoda K, Hodsman G P., Sumithran E, Johnston C I. Atrial natriuretic peptide in chronic heart failure in the rat: a correlation with ventricular dysfunction. Circ Res 1986; 59: 155–61
   Google Scholar
• Tikkanen T, Tikkanen I, Fyhrquist F. Elevated plasma natriuretic peptide in rats with myocardial infarcts. Life Sci 1987; 40: 659–63
   PubMed Web of Science ®Google Scholar
• Tikkanen I, Helm K, Tikkanen T, et al. Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor. J Pharmacol Exp Ther 1990; 254: 641–645
   PubMedGoogle Scholar
• Sybertz E J. SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator. Clin Nephrol 1991; 36: 187–91
   PubMedGoogle Scholar
• Tikkanen T. Effects of captopril and NaCl loading on plasma atrial natriuretic peptide (ANP) in rats with chronic heart failure. Scand J Clin Lab Invest 1989; 49: 133–20
   Google Scholar
• Tikkanen I, Fyhrquist F. Metsarinne K, Leidenius R. Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. Lancet 1985; ii: 66–9
   Google Scholar
• Tikkanen T, Tikkanen I, Fyhrquist F. Plasma atrial natriuretic peptide in DOCA-NaCl-treated rats. Acta Physiol Scand 1987; 129: 151–155
   PubMedGoogle Scholar
• Helin P, Kuoppasalmi K, Laakso J, Harkonen M. Human urinary biogenic amines and some physiological responses during situation stress. J Psycho-physiol 1988; 6: 125–32
   PubMed Web of Science ®Google Scholar
• Gottlieb S S., Weir M R. Renal effects of angioten-sin-converting enzyme inhibition in congestive heart failure. Am J Cardiol 1990; 66: 14D–21D
   Web of Science ®Google Scholar
• Smits G J., McGraw D E., Trapani A J., Blaine E B. Effect of endopeptidase 24.11 inhibition in conscious cardiomyopathic hamsters. J Pharmacol Exp Ther 1990; 254: 176–9
   PubMedGoogle Scholar
• Trippodo N C., Gabel R A., Harvey C M., Asaad M M., Rogers W L. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J Cardiovasc Pharmacol 1991; 18: 308–16
   PubMedGoogle Scholar
• Cavero P G., Margulies K B., Winaver J, Seymour A A., Delaney N G., Burnett J C. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 1990; 82: 196–201
   PubMed Web of Science ®Google Scholar
• Margulies K B., Perrella M A., McKinley L J., Burnett J C. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991; 88: 1636–42
   PubMed Web of Science ®Google Scholar
• Kromer E P., Eisner D, Kahles H W., Riegger G AJ. Effects of atriopeptidase inhibitor UK 79300 on left ventricular hydraulic load in patients with congestive heart failure. Am J Hypertens 1991; 4: 460–3
   PubMed Web of Science ®Google Scholar
• Eisner D, Mümtze A, Kromer E, Riegger G AJ. Effectiveness of endopeptidase inhibition (candox-atril) in congestive heart failure. Am J Cardiol 1992; 70: 494–8
   PubMed Web of Science ®Google Scholar
• Richards A M., Wittert G A., Crozier I G., et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993; 11: 407–16
   PubMed Web of Science ®Google Scholar
• Riegger G AJ, Eisner D, Kromer E P., et al. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal and renal effects. Circulation 1988; 77: 398–406
   PubMed Web of Science ®Google Scholar
• Fyhrquist F, Tikkanen I. Atrial natriuretic peptide in congestive heart failure. Am J Cardiol 1988; 62: 20A–24A
   PubMedGoogle Scholar
• Rentes J, Tikkanen I, Fyhrquist F, Pyorala K. Neuroendocrine activity in untreated heart failure. Br Heart J 1991; 65: 249–55
   PubMedGoogle Scholar
• Bellemann P, Nauser D. Modulation of ANP receptor-mediated cGMP accumulation by atrial natriuretic peptides and vasopressin in A10 vascular smooth muscle cells. J Receptor Res 1988; 8: 407–10
   PubMed Web of Science ®Google Scholar
• Rankin A J., McWilliam T M., Swift F V., Triggle C R. Studies of the desensitization of atrial natriuretic factor and nitroglycerin in rat aortic rings. Gen Pharmacol 1990; 21: 887–91
   PubMedGoogle Scholar
• Münzel T, Drexler H, Holz J, Kurtz S, Just H. Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure. Circulation 1991; 83: 191–201
   PubMedGoogle Scholar
• Zimmerman R S., Trippodo N S., MacPhee A A., Martinez A J., Barbee R W. High-dose atrial natriuretic factor enhances albumin escape from the systemic but not from the pulmonary circulation. Circ Res 1990; 67: 461–8
   PubMed Web of Science ®Google Scholar
• Gunning M E., Brady H R., Otuechere G, Brenner B M., Zeidel M L. Atrial natriuretic peptide 31–67) inhibits Na+ transport in rabbit inner medullary collecting duct cells. J Clin Invest 1992; 89: 1411–17
   PubMed Web of Science ®Google Scholar
• Martin D R., Pevahouse J B., Trigg D J., Vesely D L., Buerkert J E. Three peptides from the ANF prohormone NH2-terminus are natriuretic and/or kaliure-tic. Am J Physiol 1990; 258: F1401–8
   Google Scholar
• Richards A M., Tonolo G, Montorsi P, et al. Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man. J Clin Endocrin Metab 1988; 66: 465
   PubMedGoogle Scholar
• Motani J G., McAlpine H, Kennedy N, Struthers A D. Plasma brain natriuretic peptide as an indicator for angiotensin-converting enzyme inhibition after myocardial infarction. Lancet 1993; 341: 1109–13
   PubMedGoogle Scholar